Leo Cancer Care Particle Therapy Solution Marie is now 510(k) Pending
Marie, Leo Cancer Care's Upright Particle Therapy Solution
The submission is an important milestone bringing the technology one step closer to clinical use, in centers across the United States.
Stephen Towe, CEO of Leo Cancer Care shared these thoughts, 'Years of development go into changing an industry, but reaching the 510(k) pending milestone is always a wonderful celebration of everything that's been achieved over the last few years.
"This milestone marks the beginning of change for particle therapy, with the potential to take it to more patients who need it across the globe. Thanks to the relentless work of our team and partners, leading health networks are ready, and we eagerly await the FDA's decision."
What Scanning and Treating Upright Means for Treatment Delivery
The majority of radiotherapy treatments to date have been delivered with patients lying down with the radiation source rotated around them. Leo Cancer Care's solution challenges these conventions and will enable cancer patients to receive their radiation treatment seated in an upright position. The aim is to improve patient experience and comfort, increase clinical effectiveness and offer better access to radiotherapy.
Removing the need for large and expensive rotating gantries, the Leo solution utilizes a fixed radiation source and swaps machine rotation for patient rotation. With this innovation, we see particle therapy become typically one-third of the size, reducing the need for costly shielding, construction and technology, making particle therapy more accessible and affordable than ever before.
The system is positioned in the market as beam agnostic – meaning it can be placed in front of any fixed beam particle – and aims to make treatment modalities, including proton, carbon ion, neutron, and FLASH therapies, more mainstream.
Several centers that have adopted the technology across the United States eagerly await 510(k) clearance on this solution as they prepare their facilities for a planned first-in-the-world patient treatment later this year.
Photo: https://mma.prnewswire.com/media/2678637/Leo_Cancer_Care.jpg
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/leo-cancer-care-particle-therapy-solution-marie-is-now-510k-pending-302445460.html
SOURCE Leo Cancer Care
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025
Salt Lake City, Aug. 12, 2025 (GLOBE NEWSWIRE) — Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Joint comfort and flexibility are vital for maintaining an active, independent lifestyle — whether it's enjoying daily walks, engaging in sports, or simply moving through the day without stiffness. The conversation around joint health is shifting toward preventative, natural options that align with long-term wellness goals in 2025. MobilityMD has emerged as part of this dialogue, offering a joint support formula built on a foundation of purity, ingredient transparency, and thoughtful formulation. While it avoids overpromising results, the supplement positions itself within the growing category of wellness products designed to complement healthy movement and an active lifestyle. Discover how MobilityMD's carefully selected ingredients are shaping the conversation around joint wellness in 2025. SECTION 1: WHY INTEREST IN 'THE SECRET, PURE INGREDIENT TO SUPPORT HEALTHY JOINTS' IS SURGING IN 2025 Joint health has become a central focus for people of all ages in 2025 — from active adults looking to preserve mobility to those seeking extra support for daily comfort. This growing attention is reflected in online search trends, with Google reporting increases in queries like 'natural joint support,' 'supplements for flexibility,' and 'best ingredients for mobility.' The public is no longer just looking for quick fixes; instead, there is heightened curiosity around long-term strategies that integrate into a balanced, healthy lifestyle. Part of this shift comes from the broader wellness movement, where consumers prioritize transparency, clean sourcing, and minimal additives in the products they choose. Social media platforms, wellness podcasts, and fitness forums are filled with discussions comparing ingredient profiles, sharing personal experiences, and evaluating which formulas fit into individual health routines. MobilityMD has entered this conversation not by making sweeping claims, but by highlighting its focus on purity and thoughtful formulation. This aligns with the expectations of today's wellness-conscious consumers, who often seek products designed to complement an active lifestyle without relying on unnecessary fillers or synthetic additives. SECTION 2: MOBILITYMD'S INGREDIENT-FIRST RESPONSE TO THESE TRENDS MobilityMD was developed with a clear focus on sourcing and formulation choices that align with the modern consumer's expectations for clean, purposeful supplementation. Rather than relying on heavily processed or synthetic compounds, the formula incorporates naturally derived ingredients that have been historically discussed for their association with mobility and joint comfort. Each component is chosen with the intent to complement an active lifestyle while avoiding unnecessary additives that do not contribute to the product's purpose. The ingredient selection process emphasizes purity and transparency. This includes providing clear information about sourcing, composition, and function so that consumers can make informed choices about what they put into their bodies. The formulation also considers how different ingredients work together, aiming for a balanced profile that fits into a variety of health routines — from daily wellness habits to more targeted mobility-focused regimens. Importantly, MobilityMD avoids making direct medical claims. Instead, it positions itself as part of a broader wellness strategy, one that supports consumers in pursuing movement-friendly lifestyles while staying mindful of ingredient integrity. Discover how MobilityMD's ingredient transparency reflects the growing demand for cleaner, more purposeful joint support supplements. SECTION 3: INGREDIENT SPOTLIGHT – WHAT'S INSIDE THE FORMULA The foundation of MobilityMD lies in a carefully curated selection of naturally derived ingredients, each frequently discussed in wellness circles for their historical associations with joint comfort and mobility. While the product avoids making direct health claims, it draws on a blend that reflects both tradition and modern supplement formulation trends. Key components often include botanical extracts that have been explored for their potential to support overall wellness, minerals that play a role in maintaining balanced body functions, and naturally occurring compounds that have been studied for their relevance to healthy aging. Each ingredient is chosen with attention to purity, potency, and its ability to integrate seamlessly into a daily health regimen. MobilityMD also emphasizes the importance of what's left out of the formula. There are no unnecessary fillers, artificial colors, or synthetic preservatives — a choice that resonates with consumers who are mindful of every element they consume. This focus on clean composition positions the supplement within the growing category of wellness products designed for individuals who prioritize ingredient integrity as much as potential functional benefits. SECTION 4: WHAT REDDIT, PODCASTS & TIKTOK CREATORS ARE SAYING Conversations about joint health supplements have expanded well beyond traditional advertising channels in 2025. On Reddit, wellness and fitness communities are filled with discussions about ingredient quality, transparency, and the importance of long-term consistency in supplementation. Users frequently share their experiences with products that align with clean-label trends, and MobilityMD has been mentioned in threads that focus on naturally derived joint support options. Podcasts in the health and wellness space often highlight how consumers are becoming more discerning about supplement choices. Guests on these shows frequently emphasize reading ingredient labels, understanding sourcing, and looking for products that complement an active lifestyle. MobilityMD's ingredient-focused approach aligns with these ongoing discussions, making it a relevant part of broader wellness dialogues. On TikTok, creators in the fitness, yoga, and lifestyle categories are producing short-form content around joint-friendly routines, mobility exercises, and supplement habits that fit into a balanced regimen. While these creators don't make specific claims about results, they often showcase how clean-label supplements can be integrated alongside movement practices to support overall wellness. Learn why MobilityMD is appearing in more conversations about clean, transparent joint support in 2025. SECTION 5: WHO MIGHT BE DRAWN TO THIS TYPE OF SUPPLEMENTATION IN 2025 MobilityMD appeals to a wide range of individuals who prioritize maintaining joint comfort and flexibility as part of their overall wellness goals. Active adults, including those who enjoy walking, hiking, yoga, or recreational sports, may be drawn to the idea of a supplement that aligns with their lifestyle without unnecessary additives. Professionals who spend long hours sitting or standing may also find the clean-label approach appealing, as they look for ways to support movement and ease in daily routines. Similarly, older adults seeking to remain active and independent often look for supplements with a transparent ingredient list that avoids synthetic fillers or artificial preservatives. The eco-conscious and health-conscious crowd is another natural audience for MobilityMD. For these individuals, supplement choice is about more than potential functional benefits — it's about knowing that the formula is built on pure, purposeful components. This aligns with the broader wellness movement of 2025, where consumers increasingly value products that support their personal health goals while also reflecting their ethical and environmental values. SECTION 6: EMERGING WELLNESS & PERFORMANCE INNOVATION – 2025 MARKET REFLECTIONS The wellness and supplement market in 2025 reflects a distinct shift toward ingredient transparency, clean-label formulations, and products that fit seamlessly into long-term health routines. Consumers are increasingly skeptical of overpromising claims and are instead prioritizing supplements that are clear about their composition and intended role in a balanced lifestyle. This has created a strong market for products like MobilityMD, which position themselves as part of a broader wellness toolkit rather than a one-step solution. This trend is driven in part by the rise of self-education in health and nutrition. With more information available online than ever before, people are researching ingredients, comparing labels, and making purchasing decisions based on both scientific discussion and personal values. Social media platforms, wellness blogs, and community forums all contribute to this heightened awareness, creating a consumer base that demands higher standards from supplement brands. Within this environment, joint health remains a high-priority category. As active lifestyles, desk-based work, and healthy aging all intersect, the demand for products that align with everyday mobility needs continues to grow. MobilityMD's focus on purity and purposeful formulation allows it to stand out in a competitive market where consumers are looking for supplements that are as trustworthy as they are functional. Discover why MobilityMD is part of the new wave of clean, ingredient-first wellness products in 2025. SECTION 7: THE PUBLIC DEBATE AROUND JOINT HEALTH SUPPLEMENTS – SIGNALS, SKEPTICISM, AND SATURATION The conversation around joint health supplements in 2025 is both active and divided. Supporters often point to the importance of staying proactive with mobility support, highlighting the role of clean, naturally derived ingredients in long-term wellness routines. They value brands that offer transparency and avoid unnecessary additives, seeing these products as part of a broader strategy to maintain active, comfortable movement. Skeptics, however, question whether supplements are necessary for everyone and emphasize the need for realistic expectations. They often stress that lifestyle habits — such as regular movement, balanced nutrition, and proper hydration — form the foundation of joint health, with supplementation serving as a complement rather than a replacement. Neutral observers see the market as one experiencing rapid expansion, but also increased scrutiny. With many brands competing for attention, consumers are becoming more selective, favoring companies that provide clear ingredient information and maintain a consistent focus on product integrity. For products like MobilityMD, standing out means continuing to align with the values of informed, wellness-conscious buyers while avoiding overreaching claims. SECTION 8: ABOUT MOBILITYMD MobilityMD was created with a clear mission — to offer a joint support supplement that prioritizes purity, ingredient transparency, and alignment with modern wellness values. The brand focuses on sourcing naturally derived components that have been historically discussed in wellness communities for their association with mobility and comfort, while avoiding unnecessary additives or synthetic fillers. Every aspect of the product, from formulation to packaging, reflects a commitment to integrity. MobilityMD positions itself not as a quick-fix solution, but as part of a balanced lifestyle that may include movement practices, mindful nutrition, and regular self-care. By maintaining a clear, educational approach to its ingredients and purpose, the brand builds trust with consumers seeking a supplement that fits seamlessly into their long-term wellness routines. In a supplement landscape crowded with exaggerated promises, MobilityMD stands out for its straightforward, ingredient-first philosophy — offering a choice for those who value both product quality and transparency. See how MobilityMD's ingredient-focused approach is resonating with today's wellness-conscious consumers. SECTION 9: CONTACT MobilityMD – Clean, Ingredient-First Joint Support – Clean, Ingredient-First Joint Support Email: [email protected] Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
CNBC
6 hours ago
- CNBC
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says
Key Points The Food and Drug Administration is considering revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many kids with no available shots against the virus, though Moderna's shot will be an option for those at increased risk of severe illness due to at least one underlying condition. It would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, took the helm. In this article PFE Follow your favorite stocksCREATE FREE ACCOUNT A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine's Southern Cooking in Chatham, Illinois, Dec. 30, 2021. Brian Cassella | Tribune News Service | Getty Images The Food and Drug Administration is considering revoking its authorization of Pfizer 's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization. If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, took the helm. HHS did not immediately respond to a request for comment. The FDA told Pfizer it might not renew its longstanding emergency use authorization for children ages 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is "currently in discussions with the agency on potential paths forward." The company said that the FDA's "deliberations" are not related to the safety and efficacy of the shot, "which continues to demonstrate a favorable profile." The Guardian first reported on the FDA's potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported Saturday. In July, the FDA granted full approval to Moderna's Covid vaccine for children — but only for those with one more more health conditions that may put them at increased risk of severe illness if they become infected. The shots from both Moderna and Pfizer use messenger RNA technology. Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs. Meanwhile, Novavax 's protein-based shot has never been available for children under 12. In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. But in updated guidance days later, the CDC said the shots "may" be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults.
Yahoo
7 hours ago
- Yahoo
Speed of improvement in cancer survival rates ‘slowing', say experts
Progress in cancer survival rates in the UK has 'slowed down', experts have warned. The news comes as a study suggests survival between the most and least deadly types of the disease is wider than ever before. A national cancer plan was 'essential' to 'bring cancer survival trends back towards the best in the world', researchers said. The study, led by the London School of Hygiene and Tropical Medicine (LSHTM) and funded by Cancer Research UK, analysed long-term trends in the cancer survival index (CSI) for adults across England and Wales from 1971 to 2018. Using records from the National Disease Registration Service for England and the Welsh Cancer Intelligence and Surveillance Unit, experts estimated net survival for up to 10 years after diagnosis for around 10.8 million people. They found that in 2018, the CSI for all cancers combined a decade after diagnosis was 49.8%, higher than the CSI at one year for those diagnosed in 1971/72. Researchers hailed the figure as 'remarkable', but warned that the 'speed of improvement in survival has slowed down'. In the five years from 2000/01 to 2005/06, the 10-year CSI rose by 4%, from 41.2% to 45.2%. But between 2010/11 and 2015/16, the rise was 1.4%, from 47.9% to 49.3%. There were also major gaps in survival when it came to different cancer types. For example, 10-year survival for testicular cancer was 97%, compared with 4.3% for pancreatic cancer. Screening programmes had bolstered survival rates for cancers in the breast, bowel and cervix, according to Cancer Research UK. But survival for other types, such as stomach, lung and brain cancer, had increased by only a small amount in the past 50 years. Writing in the Lancet Regional Health – Europe, researchers warned this slowdown for individual cancers implied a 'system-wide challenge'. Michelle Mitchell, chief executive of Cancer Research UK, said: 'Thanks to research, most patients today are far more likely to survive their cancer than at any point in the past. 'But the reality is that this progress is slowing – and for some cancers, it never got going in the first place.' The Government launched a call for evidence to help shape a national cancer plan in February. The blueprint aims to outline actions to transform how the disease is treated in a bid to reduce deaths. Ms Mitchell said: 'The upcoming National Cancer Plan for England must include commitments to spot more cancers earlier, as well as backing research into new treatments so that each patient, regardless of their diagnosis, can hope for more moments with the people they love.' Michel Coleman, a professor of epidemiology and statistics at LSHTM, said: 'Since I began my career in cancer research, I've seen substantial increases in survival for most types of cancer. 'Our understanding of cancer biology has expanded, effective screening programmes have been introduced, and new treatments have been developed. Allowing this trend to stall will have devastating consequences. 'This study was only possible because of data on millions of patients from cancer registries in England and Wales. 'It's vital that the Government provides the political and financial support to ensure we maintain this crucial data. Without these, the Government will be flying blind on cancer control. 'The National Cancer Plan is a chance to improve NHS cancer pathways and reap the benefits of new research – the Government must take it.' Cancer Research UK is calling for the national cancer plan to slash waiting times for diagnosis and treatment, saying some patients face unacceptable delays. The plan should also improve early diagnosis of cancer, with plans to boost participation in existing screening programmes and a commitment to rolling out lung cancer screening fully in England by 2029. A Department of Health and Social Care spokesperson said: 'We are prioritising cancer care as we turn around more than a decade of neglect of our NHS. 'We're already seeing progress, with 95,000 more people having cancer diagnosed or ruled out within 28 days between July 2024 and May 2025, compared to the same period the previous year. 'The National Cancer Plan will set out how we will improve survival rates further and address the variation between different cancer types.'
